×
Please click
here
if you are not redirected within a few seconds.
All
Maps
News
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Merrimack Pharma Plans to Delist, Pending Holder Approval of Liquidation Plan
MarketWatch
By Stephen Nakrosis Merrimack Pharmaceuticals on Tuesday said it filed with the Nasdaq regarding the company's plan to delist its securities...
1 month ago
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating ...
Yahoo Finance
CAMBRIDGE, Mass., May 10, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the...
3 weeks ago
Merrimack to dissolve after FDA nod prompts $225 million payment By Investing.com
Investing.com
CAMBRIDGE, Mass. - Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) has announced that it will receive a milestone payment of $225 million from...
3 months ago
Merrimack Pharmaceuticals stockholders approve plan of dissolution (NASDAQ:MACK)
Seeking Alpha
Merrimack Pharmaceuticals (MACK) stockholders approve dissolution plan; liquidating cash dividend of $15.10/share declared.
3 weeks ago
FDA Approves New First-Line Med for Pancreatic Cancer as Drug’s Initial Developer Dissolves
MedCity News
Pancreatic cancer continues to be one of the most difficult-to-treat cancers. An Ipsen drug is now approved as a first-line therapy,...
3 months ago
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to ...
Business Wire
In the event that the Company's stockholders do not approve the Plan of Dissolution, Merrimack will withdraw its notice to NASDAQ of its intent...
1 month ago
With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer
Fierce Pharma
It's the approval Ipsen has been waiting for since buying up Onivyde in 2017. The FDA has approved Onivyde as part of a multidrug...
3 months ago
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of ...
Yahoo Finance
Our data indicates that hedge funds own 35% of Merrimack Pharmaceuticals. That's interesting, because hedge funds can be quite active and...
2 months ago
Merrimack stock spikes as FDA expands Onivyde label
Seeking Alpha
Merrimack Pharmaceuticals (MACK) stock rises as U.S. FDA approves expansion of pancreatic cancer therapy Onivyde. Read more here.
3 months ago
Shares of Merrimack soar after cancer drug succeeds in trial
STAT
Shares of Merrimack Pharmaceuticals, a shuttered drug company with no employees or any active research programs, more than doubled Wednesday...
18 months ago